Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;2(3):90-7.
doi: 10.1002/emmm.201000061.

The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy

Rob Ofman  1 , Inge M E Dijkstra, Carlo W T van Roermund, Nena Burger, Marjolein Turkenburg, Arno van Cruchten, Catherine E van Engen, Ronald J A Wanders, Stephan Kemp
Affiliations

The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy

Rob Ofman et al. EMBO Mol Med. 2010 Mar.

Abstract

X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene encoding the peroxisomal ABC transporter adrenoleukodystrophy protein (ALDP). X-ALD is characterized by the accumulation of very long-chain fatty acids (VLCFA; > or =C24) in plasma and tissues. In this manuscript we provide insight into the pathway underlying the elevated levels of C26:0 in X-ALD. ALDP transports VLCFacyl-CoA across the peroxisomal membrane. A deficiency in ALDP impairs peroxisomal beta-oxidation of VLCFA but also raises cytosolic levels of VLCFacyl-CoA which are substrate for further elongation. We identify ELOVL1 (elongation of very-long-chain-fatty acids) as the single elongase catalysing the synthesis of both saturated VLCFA (C26:0) and mono-unsaturated VLCFA (C26:1). ELOVL1 expression is not increased in X-ALD fibroblasts suggesting that increased levels of C26:0 result from increased substrate availability due to the primary deficiency in ALDP. Importantly, ELOVL1 knockdown reduces elongation of C22:0 to C26:0 and lowers C26:0 levels in X-ALD fibroblasts. Given the likely pathogenic effects of high C26:0 levels, our findings highlight the potential of modulating ELOVL1 activity in the treatment of X-ALD.

PubMed Disclaimer

Figures

Figure 1
Figure 1. D3-VLCFA levels in control and X-ALD fibroblasts

  1. D3-C22:0 levels in control versus X-ALD cell lines.

  2. D3-C26:0 levels in control versus X-ALD cell lines.

  3. D3-C26:0/D3-C22:0 ratio in control versus X-ALD cell lines.

    Eight control and 25 X-ALD cell lines were cultured for 72 h with 50 µM D3-C16:0. Fatty acids are in nmol/mg protein. Data are mean ± SD. **p < 0.01, ***p < 0.001 by unpaired student's t-test.

Figure 2
Figure 2. VLCFacyl-CoA levels are increased in X-ALD fibroblasts

  1. Pristanoyl-CoA levels in control versus X-ALD cell lines.

  2. C24:0-CoA levels in control versus X-ALD cell lines.

  3. C26:0-CoA levels in control versus X-ALD cell lines.

  4. Fatty acyl-CoAs are in pmol/mg protein. Data are mean ± SD in 3 control and 6 X-ALD cell lines. ***p < 0.001 by unpaired student's t-test.

Figure 3
Figure 3. ELOVL1 expression is not increased in X-ALD fibroblasts

  1. ELOVL1 mRNA expression in 6 control and 9 X-ALD cell lines. Data are mean ± SD.

  2. ELOVL1 protein expression in control and X-ALD cell lines. (+) positive control: CHO cells expressing ELOVL1.

Figure 4
Figure 4. ELOVL1 knockdown reduces C26:0 levels in X-ALD fibroblasts

  1. ELOVL1 expression in X-ALD fibroblasts cultured for 3, 4, 5 or 6 days in medium devoid of (−) or supplemented with (+) ELOVL1 siRNA.

  2. ELOVL1 expression in X-ALD fibroblasts which were untransfected (−) or transfected (+) with siRNA targeting either cyclophilin-B (control) or ELOVL1.

  3. Effect of control siRNA (white bars) or ELOVL1 siRNA (grey bars) on cell proliferation in comparison with untransfected cells (black bars).

  4. D3-C26:0 levels in ELOVL1 siRNA transfected (grey bars) versus untransfected (black bars) X-ALD fibroblasts.

  5. C26:0 levels in control and X-ALD fibroblasts which were untransfected (black bars) and in X-ALD fibroblasts which were transfected with either control siRNA (white bars) or ELOVL1 siRNA (grey bars). Fatty acids are in nmol/mg protein. Data are mean ± SD. ***p < 0.001 by unpaired student's t-test.

See this image and copyright information in PMC

References

    1. Agbaga MP, Brush RS, Mandal MN, Henry K, Elliott MH, Anderson RE. Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. PNAS. 2008;105:12843–12848. - PMC - PubMed
    1. Asheuer M, Bieche I, Laurendeau I, Moser A, Hainque B, Vidaud M, Aubourg P. Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum Mol Genet. 2005;14:1293–1303. - PubMed
    1. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaque I, Jakobezak C, Lemaitre A, Boureau F, Wolf C. A two-year trial of oleic and erucic acids (“Lorenzo's oil”) as treatment for adrenomyeloneuropathy. N Engl J Med. 1993;329:745–752. - PubMed
    1. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326:818–823. - PubMed
    1. Engelen M, Ofman R, Mooijer PAW, Poll-The BT, Wanders RJA, Kemp S. Cholesterol-deprivation increases mono-unsaturated very long-chain fatty acids in skin fibroblasts from patients with X-linked adrenoleukodystrophy. Biochim Biophys Acta. 2008;1781:105–111. - PubMed

Publication types

MeSH terms

Substances